

RESEARCH**BOB ECONOMICS RESEARCH | FY25 BUDGET PREVIEW**

Focus to remain on consolidation

OIL & GAS | Q1FY25 PREVIEW

Q1FY25 marks normalisation of margins in oil & gas

HCL TECHNOLOGIES | NOT RATED

1QFY25 broadly in line. No material change in demand

SUMMARY**INDIA ECONOMICS: FY25 BUDGET PREVIEW**

The main budget for 2024-25 is most likely to shed light on vision of the government for the next five years and bring to focus the key themes that will help achieve the dream of making India a 'Viksit Bharat' by 2047. This budget will remain committed to the path of fiscal consolidation, and inch closer to the FY26 target of <4.5%, by bringing the fiscal deficit in FY25 to 4.9-5.1%, from 5.2% in interim budget (GDP for FY24 came in lower than what was assumed in the Interim Budget). This will be helped by additional fiscal space made available by RBI's more than estimated surplus transfer and hopes of better than expected GDP growth this year.

[Click here](#) for the full report.

OIL & GAS: Q1FY25 PREVIEW

- Refining, marketing and gas distribution margins have normalised in Q1 and are likely to still remain in the healthy range
- Investors' focus on volume growth likely to improve. RIL, PLNG and CGDs in our coverage are key contenders for growth ahead
- Growth in consumer and New Energy for RIL, pace of volume ramp-up for CGD and impact of make-up cargoes on PLNG are key monitorables

[Click here](#) for the full report.



HCL TECHNOLOGIES

- 1QFY25 revenue and margins were broadly along expected lines. Full-year revenue and growth guidance maintained
- Points to weakness in Auto ERDS space in Europe in EVs. Also indicates irrational competitive intensity in ADM/IMS renewals
- Client breadth is very narrow and like that of TCS. We are in the process of initiating coverage on the sector and on HCLT

[Click here](#) for the full report.

FY25 BUDGET PREVIEW

12 July 2024

Focus to remain on consolidation

The main budget for 2024-25 is most likely to shed light on vision of the government for the next five years and bring to focus the key themes that will help achieve the dream of making India a 'Viksit Bharat' by 2047. This budget will remain committed to the path of fiscal consolidation, and inch closer to the FY26 target of <4.5%, by bringing the fiscal deficit in FY25 to 4.9-5.1%, from 5.2% in interim budget (GDP for FY24 came in lower than what was assumed in the Interim Budget). This will be helped by additional fiscal space made available by RBI's more than estimated surplus transfer and hopes of better than expected GDP growth this year.

Sonal Badhan
Economist

Normal monsoon, gradual decline in inflation, softening of interest rates and government's measures to boost consumption and investment will aid growth this year. As a result, enhanced spending on MGNREGA, PM KISAN, and PMAY can be expected. We also expect capex at Rs 11.2-11.3 lakh crore for this year, to help crowd-in private investments. Markets will keep a watchful eye on borrowings which can change in case the fiscal deficit is altered from 5.2% as per the Interim Budget. Also the sharing of the total borrowings between market and small savings would be of interest.

Expectations from final FY25 Budget

Since the latest budget presentation for 2024-25 (FY25) will be the 1st after government begins its third term, we expect the budget to be more of a visionary document, presenting key focus areas for the new government.

First and foremost, it will continue to adhere to the path of fiscal consolidation, without compromising on the quality of expenditure. As a result, we expect 10-30bps reduction in the fiscal deficit (% of GDP) target to 4.9-5.1%. Given the extra fiscal room available with the government from additional Rs 1 lakh crore surplus from RBI we can expect announcements to boost consumption, saving and investment. If the budget assumes GDP level for FY25 to be at the level of Rs 327.7 lakh crore as per the Interim Budget the implicit GDP growth rate would be 11%. However, if the forecast of growth is increased to 11.5%, then GDP would be Rs 329.3 lakh crore which would then offer more space for the fiscal deficit. This combined space will vary from Rs 1-2.6 lakh crore depending on the forecast made for GDP growth.

These savings can be used for lowering the fiscal deficit target, making allowances for higher expenditure, lower collections on disinvestment or loss of revenue due to tax concessions.



Q1FY25 marks normalisation of margins in oil & gas

- Refining, marketing and gas distribution margins have normalised in Q1 and are likely to still remain in the healthy range
- Investors' focus on volume growth likely to improve. RIL, PLNG and CGDs in our coverage are key contenders for growth ahead
- Growth in consumer and New Energy for RIL, pace of volume ramp-up for CGD and impact of make-up cargoes on PLNG are key monitorables

Kirtan Mehta, CFA
 research@bobcaps.in

Margins normalise in Q1FY25: We forecast a 29% YoY decline in EBITDA across our coverage universe, driven by 57% pullback in oil marketing companies and 25% decline in city gas distribution. Sequentially, we estimate a 10% drop in EBITDA for our coverage. RIL and PLNG are likely to stand-out with positive YoY growth.

RIL to post modest YoY growth: We expect RIL to post 4% YoY EBITDA growth as consumer businesses and oil & gas production offset the decline in O2C margins. RIL is likely to see a 7% QoQ contraction in EBITDA on weaker refining margins. Commentary on 5G penetration, roll-out of Jio AirFiber, subscriber consolidation, start-up of giga factories and listing of Digital and Retail are key monitorables.

OMC margins to normalise: We build in a 57% YoY/17% QoQ decline in OMCs EBITDA in Q1 with a simultaneous easing of refining and marketing margins. While refining margin comes off the high base with the ramp-up of a couple of global refineries, marketing margin eases due to retail price cuts in March (LPG to play a larger role). R&M EBITDA margin is still likely to remain healthy at Rs4.2k/t or US\$6.9/bbl of marketing volume at our estimates. Delivery timelines on expansion projects and commentary on stability of marketing margin are key monitorables.

CGDs to see modest volume growth, normalisation of margins: Collectively for IGL and MAHGL, we build in a 25% YoY/ 5% QoQ decline in EBITDA. Margins are likely to decline due to reduction in CNG prices, higher shortage of APM gas and increase in spot LNG prices. We factor in an EBITDA margin of Rs 10.6/scm for MAHGL and Rs6.2/scm for IGL in Q1FY25. Commentary on the pace of CNG vehicle additions, additional success in the industrial segment, availability of APM gas and guidance on EBITDA margin are key monitorables.

Other gas utilities: Benefitting from a surge in LNG consumption, PLNG is likely to clock 19% YoY/11% QoQ growth in adj EBITDA ex provisions for TOP recovery. In contrast, GUJS is likely to post a sharp 34% YoY/42% QoQ cut in EBITDA impacted by the [recent cut in HP Gas Grid's tariff](#). Actual underlying tariff post cut and volume outlook is key for GUJS; visibility on [timing for make-up cargoes](#) is key for PLNG.



NOT RATED**HCL TECHNOLOGIES**

| IT Services

| 13 July 2024

1QFY25 broadly in line. No material change in demand

- 1QFY25 revenue and margins were broadly along expected lines. Full-year revenue and growth guidance maintained
- Points to weakness in Auto ERDS space in Europe in EVs. Also indicates irrational competitive intensity in ADM/IMS renewals
- Client breadth is very narrow and like that of TCS. We are in the process of initiating coverage on the sector and on HCLT

Girish Pai

research@bobcaps.in

HCLT's revenue declined less than expected: HCLT's 1QFY25 revenue decline of 1.6% in constant currency (CC) terms was a tad better than its guidance of 2% decline. EBIT margin at 17.1% came in a tad below our estimate of 17.4%. HCLT's top five clients drove growth in the quarter. PAT beat was driven by other income from the State Street divestment. HCLT held on to its FY25 guidance of 3-5% CC revenue growth and 18-19% EBIT margin growth. Consensus EPS for FY25 will stay put post 1QFY25, in our view.

Deals got pushed out: The order inflow at ~US\$ 1.96bn came in at the lower end of our expected range (US\$ 2bn-2.5bn) as it saw some deals being pushed out (like what TCS indicated).

Seasonal weakness comes into play: HCLT saw US\$ QoQ weakness in BFSI (-4.7%), Manufacturing (-6.7%) and Life Sciences and Healthcare (-4.3%). The decline in BFSI was driven by the offshoring of a large client. The manufacturing decline was due to productivity gains being passed back to clients (typical during this time of the fiscal year), weakness in the auto segment (European) and asset revenue falling QoQ (US\$ 10mn). Pressure from the Med-tech business led to the decline in the Life Sciences and Healthcare parts of the business.

Broadbased growth indicated for 2QFY25: HCLT sees broad-based QoQ revenue growth in 2QFY25 across verticals and geographies. The only vertical that is not likely to grow QoQ will be BFSI because of the impact of the State Street divestiture (80bps impact).


Demand conditions remain the same: HCLT indicated the business environment would be like what it was over the last few quarters – echoing the commentary of TCS.

Discretionary spends still under pressure: Management indicated discretionary spending would be under pressure, though there were a few pockets where such spends would happen. Especially if that led to cost benefits for the customer.

Ticker/Price	HCLT IN/Rs 1,560
Market cap	US\$ 51.5bn
Free float	38%
3M ADV	US\$ 69.8mn
52wk high/low	Rs 1,697/Rs 1,087
Promoter/FPI/DII	61%/17%/22%

Source: NSE | Price as of 11 Jul 2024

Stock performance



Source: NSE



NOT FOR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OF AMERICA (“US”) OR IN OR INTO ANY OTHER JURISDICTION IF SUCH AN ACTION IS PROHIBITED BY APPLICABLE LAW.

Disclaimer

Name of the Research Entity: **BOB Capital Markets Limited**

Registered office Address: **1704, B Wing, Parinee Crescenzo, G Block, BKC, Bandra East, Mumbai 400051**

SEBI Research Analyst Registration No: **INH000000040 valid till 03 February 2025**

Brand Name: **BOBCAPS**

Trade Name: **www.barodaetrade.com**

CIN: **U65999MH1996GOI098009**

Logo:  **BOBCAPS**
 TRUST | INNOVATION | EXCELLENCE

Investments in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Recommendation scale: Recommendations and Absolute returns (%) over 12 months

BUY – Expected return >+15%

HOLD – Expected return from -6% to +15%

SELL – Expected return <-6%

Note: Recommendation structure changed with effect from 21 June 2021

Our recommendation scale does not factor in short-term stock price volatility related to market fluctuations. Thus, our recommendations may not always be strictly in line with the recommendation scale as shown above.

Analyst certification

Each of the analysts mentioned in this research report certify, with respect to the sections of the report for which they are responsible, that (1) all of the views expressed in this report accurately reflect his/her personal views about the subject company or companies and its or their securities, and (2) no part of his/her compensation was, is, or will be, directly or indirectly, related to the specific recommendation(s) or view(s) in this report. Analysts are not registered as research analysts by FINRA and are not associated persons of BOB Capital Markets Limited (BOBCAPS).

Important disclosures

This product is a compilation of previously published research notes. To view the complete report along with the associated Analyst certifications and Company-specific disclosures, please click on the hyperlink accompanying each excerpt.

General disclaimers

BOBCAPS is engaged in the business of Stock Broking and Investment Banking. BOBCAPS is a member of the National Stock Exchange of India Limited and BSE Limited and is also a SEBI-registered Category I Merchant Banker. BOBCAPS is a wholly owned subsidiary of Bank of Baroda which has its various subsidiaries engaged in the businesses of stock broking, lending, asset management, life insurance, health insurance and wealth management, among others.

BOBCAPS's activities have neither been suspended nor has it defaulted with any stock exchange authority with whom it has been registered in the last five years. BOBCAPS has not been debarred from doing business by any stock exchange or SEBI or any other authority. No disciplinary action has been taken by any regulatory authority against BOBCAPS affecting its equity research analysis activities.

BOBCAPS is also a SEBI-registered intermediary for the broking business having SEBI Single Registration Certificate No.: INZ000159332 dated 20 November 2017.

BOBCAPS prohibits its analysts, persons reporting to analysts, and members of their households from maintaining a financial interest in the securities or derivatives of any companies that the analysts cover. Additionally, BOBCAPS prohibits its analysts and persons reporting to analysts from serving as an officer, director, or advisory board member of any companies that the analysts cover.

Our salespeople, traders, and other professionals may provide oral or written market commentary or trading strategies to our clients that reflect opinions contrary to the opinions expressed herein, and our proprietary trading and investing businesses may make investment decisions that are inconsistent with the recommendations expressed herein. In reviewing these materials, you should be aware that any or all of the foregoing, among other things, may give rise to real or potential conflicts of interest. Additionally, other important information regarding our relationships with the company or companies that are the subject of this material is provided herein.

This material should not be construed as an offer to sell or the solicitation of an offer to buy any security in any jurisdiction We are not soliciting any action based on this material. It is for the general information of BOBCAPS's clients. It does not constitute a personal recommendation or take into account the particular investment objectives, financial situations, or needs of individual clients. Before acting on any advice or recommendation in this material, clients should consider whether it is suitable for their particular circumstances and, if necessary, seek professional advice. BOBCAPS research reports follow rules laid down by Securities and Exchange Board of India and individuals employed as research analysts are separate from other employees who are performing sales trading, dealing, corporate finance advisory or any other activity that may affect the independence of its research reports.

The price and value of the investments referred to in this material and the income from them may go down as well as up, and investors may realize losses on any investments. Past performance is not a guide for future performance, future returns are not guaranteed and a loss of original capital may occur. BOBCAPS does not provide tax advice to its clients, and all investors are strongly advised to consult with their tax advisers regarding any potential investment in certain transactions — including those involving futures, options, and other derivatives as well as non-investment-grade securities — that give rise to substantial risk and are not suitable for all investors. The material is based on information that we consider reliable, but we do not represent that it is accurate or complete, and it should not be relied on as such. Opinions expressed are our current opinions as of the date appearing on this material only. We endeavour to update on a reasonable basis the information discussed in this material, but regulatory, compliance, or other reasons may prevent us from doing so.

We and our affiliates, officers, directors, and employees, including persons involved in the preparation or issuance of this material, may from time to time have “long” or “short” positions in, act as principal in, and buy or sell the securities or derivatives thereof of companies mentioned herein and may from time to time add to or dispose of any such securities (or investment). We and our affiliates may assume an underwriting commitment in the securities of companies discussed in this document (or in related investments), may sell them to or buy them from customers on a principal basis, and may also perform or seek to perform investment banking or advisory services for or relating to these companies and may also be represented in the supervisory board or any other committee of these companies.

For the purpose of calculating whether BOBCAPS and its affiliates hold, beneficially own, or control, including the right to vote for directors, one per cent or more of the equity shares of the subject company, the holdings of the issuer of the research report is also included.

BOBCAPS and its non-US affiliates may, to the extent permissible under applicable laws, have acted on or used this research to the extent that it relates to non-US issuers, prior to or immediately following its publication. Foreign currency denominated securities are subject to fluctuations in exchange rates that could have an adverse effect on the value or price of or income derived from the investment. In addition, investors in securities such as ADRs, the value of which are influenced by foreign currencies, effectively assume currency risk. In addition, options involve risks and are not suitable for all investors. Please ensure that you have read and understood the Risk disclosure document before entering into any derivative transactions.

No part of this material may be (1) copied, photocopied, or duplicated in any form by any means or (2) redistributed without BOBCAPS's prior written consent.

Other disclosures

BOBCAPS does not have any financial interest in the subject company. BOBCAPS does not have actual/beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS is not engaged in any market making activities for the subject company.

BOBCAPS or its associates may have material conflict of interest at the time of publication of this research report.

BOBCAPS's associates may have financial interest in the subject company. BOBCAPS's associates may hold actual / beneficial ownership of one per cent or more securities in the subject company at the end of the month immediately preceding the date of publication of this report.

BOBCAPS or its associates may have managed or co-managed a public offering of securities for the subject company or may have been mandated by the subject company for any other assignment in the past 12 months.

BOBCAPS may have received compensation from the subject company in the past 12 months. BOBCAPS may from time to time solicit or perform investment banking services for the subject company. BOBCAPS or its associates may have received compensation from the subject company in the past 12 months for services in respect of managing or co-managing public offerings, corporate finance, investment banking or merchant banking, brokerage services or other advisory services in a merger or specific transaction. BOBCAPS or its associates may have received compensation for products or services other than investment banking or merchant banking or brokerage services from the subject company in the past 12 months.

Other disclaimers

BOBCAPS and MAYBANK (as defined below) make no representation or warranty, express or implied, as to the accuracy or completeness of any information obtained from third parties and expressly disclaim the merchantability, suitability, quality and fitness of this report. The information in this report has not been independently verified, is provided on an "as is" basis, should not be relied on by you in connection with any contract or commitment, and should not be used as a substitute for enquiries, procedures and advice which ought to be undertaken by you. This report also does not constitute an offer or solicitation to buy or sell any securities referred to herein and you should not construe this report as investment advice. All opinions and estimates contained in this report constitute BOBCAPS's judgment as of the date of this report and are subject to change without notice, and there is no obligation on BOBCAPS or MAYBANK to update this report upon issuance. This report and the information contained herein may not be reproduced, redistributed, disseminated or copied by any means without the prior consent of BOBCAPS and MAYBANK.

To the full extent permitted by law neither BOBCAPS, MAYBANK nor any of their respective affiliates, nor any other person, accepts any liability howsoever arising, whether in contract, tort, negligence, strict liability or any other basis, including without limitation, direct or indirect, special, incidental, consequential or punitive damages arising from any use of this report or the information contained herein. By accepting this report, you agree and undertake to fully indemnify and hold harmless BOBCAPS and MAYBANK from and against claims, charges, actions, proceedings, losses, liabilities, damages, expenses and demands (collectively, the "Losses") which BOBCAPS and/or MAYBANK may incur or suffer in any jurisdiction including but not limited to those Losses incurred by BOBCAPS and/or MAYBANK as a result of any proceedings or actions brought against them by any regulators and/or authorities, and which in any case are directly or indirectly occasioned by or result from or are attributable to anything done or omitted in relation to or arising from or in connection with this report.

Distribution into the United Kingdom ("UK"):

This research report will only be distributed in the United Kingdom, in accordance with the applicable laws and regulations of the UK, by Maybank Securities (London) Ltd ("MSL") who is authorised and regulated by the Financial Conduct Authority ("FCA") in the United Kingdom (MSL and its affiliates are collectively referred to as "MAYBANK"). BOBCAPS is not authorized to directly distribute this research report in the UK.

This report has not been prepared by BOBCAPS in accordance with the UK's legal and regulatory requirements.

This research report is for distribution only to, and is solely directed at, selected persons on the basis that those persons: (a) are eligible counterparties and professional clients of MAYBANK as selected by MAYBANK solely at its discretion; (b) have professional experience in matters relating to investments falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005, as amended from time to time (the "Order"), or (c) fall within Article 49(2)(a) to (d) (high net worth companies, unincorporated associations, etc. as mentioned in the stated Article) of the Order; (all such persons together being referred to as "relevant persons").

This research report is directed only at relevant persons and must not be acted on or relied on by any persons who are not relevant persons. Any investment or investment activity to which this material relates is available only to relevant persons and will be engaged in only with relevant persons.

The relevant person as recipient of this research report is not permitted to reproduce, change, remove, pass on, distribute or disseminate the data or make it available to third parties without the written permission of BOBCAPS or MAYBANK. Any decision taken by the relevant person(s) pursuant to the research report shall be solely at their costs and consequences and BOBCAPS and MAYBANK shall not have any liability of whatsoever nature in this regard.

No distribution into the US:

This report will not be distributed in the US and no US person may rely on this communication.

Other jurisdictions:

This report has been prepared in accordance with SEBI (Research Analysts) Regulations and not in accordance with local regulatory requirements of any other jurisdiction. In any other jurisdictions, this report is only for distribution (subject to applicable legal or regulatory restrictions) to professional, institutional or sophisticated investors as defined in the laws and regulations of such jurisdictions by Maybank Securities Pte Ltd. (Singapore) and / or by any broker-dealer affiliate or such other affiliate as determined by Malayan Banking Berhad.

If the recipient of this report is not as specified above, then it should not act upon this report and return the same to the sender.

By accepting this report, you agree to be bound by the foregoing limitations.